1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 1,256 | 1,294 | 23.05. | |
| 1,264 | 1,300 | 22.05. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 06.05. | SynAct Pharma AB: SynAct Pharma completes dosing for last patient in Phase 2b ADVANCE study | 138 | GlobeNewswire (Europe) | SynAct Pharma AB (publ) ("SynAct") (Nasdaq Stockholm: SYNACT), a clinical-stage biotechnological company focused on treating inflammation through resolution therapy, has successfully completed dosing... ► Artikel lesen | |
| 26.03. | SynAct Pharma AB: SynAct Pharma doses first patients in the Phase 2 RESOVIR-2 study with resomelagon | 204 | GlobeNewswire (Europe) | SynAct Pharma AB ("SynAct") (Nasdaq Stockholm: SYNACT), a clinical-stage biotechnological company focused on treating inflammation through resolution, today announces that the first patients were dosed... ► Artikel lesen | |
| 03.03. | SynAct Pharma - Multiple shots on goal in 2026 for resomelagon | 379 | Edison Investment Research | SynAct Pharma's FY25 results reflect a year of solid execution, highlighted by the continued advancement of lead asset resomelagon in the Phase IIb ADVANCE trial in rheumatoid arthritis (RA). With enrolment... ► Artikel lesen | |
| 24.02. | SynAct Pharma AB: SynAct Pharma appoints Ann Kristin Led as Chief Financial Officer | 164 | GlobeNewswire (Europe) | SynAct Pharma AB (publ) ("SynAct") (Nasdaq Stockholm: SYNACT), a clinical-stage biotechnological company focused on treating inflammation through resolution, today announced the appointment of Ann Kristin... ► Artikel lesen | |
| 18.02. | SynAct Pharma AB: SynAct Pharma Year-end Report 2025 | 163 | GlobeNewswire (Europe) | SynAct Pharma AB (publ) ("SynAct") today announced its Year-end Report 2025
"As we close the fourth quarter and conclude 2025, I am pleased with the steady progress SynAct Pharma has made across clinical... ► Artikel lesen | |
| 10.02. | SynAct Pharma - Resomelagon progresses in RA, viral infections | 431 | Edison Investment Research | SynAct Pharma has completed patient recruitment for its Phase IIb ADVANCE trial (n=240) in rheumatoid arthritis (RA), while initiating the Phase II RESPIRE study in hospitalised with respiratory insufficiency... ► Artikel lesen | |
| 06.02. | SynAct Pharma AB: SynAct Pharma successfully reached recruitment goal in Ph2b ADVANCE study | 361 | GlobeNewswire (Europe) | SynAct Pharma AB (publ) ("SynAct") (Nasdaq Stockholm: SYNACT), a clinical-stage biotechnological company focused on treating inflammation through resolution therapy, has successfully reached the recruitment... ► Artikel lesen | |
| 30.01. | SynAct Pharma AB: SynAct Pharma initiates Phase 2 study in respiratory insufficiency | 338 | GlobeNewswire (Europe) | SynAct Pharma AB (publ) ("SynAct") (Nasdaq Stockholm: SYNACT), a clinical-stage biotechnological company focused on treating inflammation through resolution therapy, today announced that it has initiated... ► Artikel lesen | |
| SYNACT PHARMA Aktie jetzt für 0€ handeln | |||||
| 19.01. | SynAct Pharma AB: SynAct Pharma appoints Malin Wikstrand as interim CFO | 205 | GlobeNewswire (Europe) | SynAct Pharma AB (publ) ("SynAct") (Nasdaq Stockholm: SYNACT), a clinical-stage biotechnological company focused on treating inflammation through resolution therapy, today announces that Malin Wikstrand... ► Artikel lesen | |
| 27.11.25 | SynAct Pharma AB: Report from the Extraordinary General Meeting of SynAct Pharma AB | 270 | GlobeNewswire (Europe) | An Extraordinary General Meeting in SynAct Pharma AB (publ) was held today, 27 November 2025, at MAQS Advokatbyrå's premises at Stureplan 19 in Stockholm. Chairperson of the General Meeting was Matilda... ► Artikel lesen | |
| 03.11.25 | SynAct Pharma AB: Resomelagon Phase-2B ADVANCE Study Update: 190 Patients Randomized Tracking for Year-End Recruitment Completion | 280 | GlobeNewswire (Europe) | SynAct Pharma AB (publ) ("SynAct") (Nasdaq Stockholm: SYNACT), a clinical-stage biotechnological company focused on treating inflammation through resolution therapy, has randomized 190 out of 240 patients... ► Artikel lesen | |
| 31.10.25 | SynAct Pharma - Approaching a catalyst-rich period | 398 | Edison Investment Research | SynAct Pharma's Q325 results underscored the company's steady progress on its clinical strategy, led by the ongoing Phase IIb ADVANCE trial evaluating resomelagon as a first-line treatment for rheumatoid... ► Artikel lesen | |
| 30.10.25 | SynAct Pharma AB: SynAct Pharma publishes Q3 2025 interim results | 215 | GlobeNewswire (Europe) | SynAct Pharma AB (publ) ("SynAct") today publishes the interim report for the third quarter 2025.
"SynAct is in a fortunate position now as the company has two development tracks, across both autoimmune... ► Artikel lesen | |
| 28.10.25 | SynAct Pharma - Differentiated inflammation resolution approach | 356 | Edison Investment Research | SynAct Pharma is focused on inflammation resolution therapeutics. Its lead asset, resomelagon, is differentiated by its novel mechanism, targeting specific melanocortin receptor subtypes believed to... ► Artikel lesen | |
| 16.09.25 | SynAct Pharma AB: SynAct Pharma's CFO Björn Westberg leaves for new leading position | 208 | GlobeNewswire (Europe) | SynAct Pharma AB (publ) ("SynAct") (Nasdaq Stockholm: SYNACT), a clinical-stage biotechnological company focused on treating inflammation through resolution therapy, today announced that the company's... ► Artikel lesen | |
| 05.09.25 | SynAct Pharma AB: SynAct appoints Mads Bjerregaard as Chief Business Officer | 250 | GlobeNewswire (Europe) | SynAct Pharma AB (publ) ("SynAct") (Nasdaq Stockholm: SYNACT), a clinical-stage biotechnological company focused on treating inflammation through resolution, today announced the appointment of Mads... ► Artikel lesen | |
| 20.08.25 | SynAct Pharma AB: SynAct Pharma publishes Q2 2025 interim results | 287 | GlobeNewswire (Europe) | SynAct Pharma AB (publ) ("SynAct") today publishes the interim report for the second quarter 2025.
"SynAct continued to strengthen its position during the second quarter, refining its development strategy... ► Artikel lesen | |
| 27.05.25 | SynAct Pharma AB: SynAct Pharma publishes Q1 2025 interim results | 323 | GlobeNewswire (Europe) | SynAct Pharma AB (publ) ("SynAct") today publishes the interim report for the first quarter 2025.
"SynAct Pharma has a remarkable drug candidate with resomelagon (AP1189). The data gained so far point... ► Artikel lesen |
18 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BAYER | 38,510 | -1,03 % | EQS-PVR: Bayer Aktiengesellschaft: Veröffentlichung gemäß § 40 Abs. 1 WpHG mit dem Ziel der europaweiten Verbreitung | EQS Stimmrechtsmitteilung: Bayer Aktiengesellschaft
Bayer Aktiengesellschaft: Veröffentlichung gemäß § 40 Abs. 1 WpHG mit dem Ziel der europaweiten Verbreitung
19.05.2026... ► Artikel lesen | |
| MERCK KGAA | 128,60 | +1,74 % | BARCLAYS stuft MERCK KGAA auf 'Equal Weight' | LONDON (dpa-AFX Analyser) - Die britische Investmentbank Barclays hat die Einstufung für Merck KGaA mit einem Kursziel von 130 Euro auf "Equal Weight" belassen. Das erste Quartal des Pharma- und Chemiekonzerns... ► Artikel lesen | |
| AKARI THERAPEUTICS | 18,230 | -0,22 % | Akari Therapeutics Plc: Akari Therapeutics Reports Breakthrough Preclinical Data Demonstrating Synergistic Activity of AKTX-101 with KRAS Inhibition in KRAS-Mutated Pancreatic Cancer Models | An ADC with a novel RNA spliceosome modulating payload PH1 paired with a KRAS inhibitor demonstrates synergistic cytotoxic activity against KRAS G12D and G12C- driven pancreatic cancer modelsData... ► Artikel lesen | |
| NOVO NORDISK | 38,660 | +1,63 % | BARCLAYS stuft NOVO NORDISK auf 'Equal Weight' | LONDON (dpa-AFX Analyser) - Die britische Investmentbank Barclays hat die Einstufung für Novo Nordisk mit einem Kursziel von 300 dänischen Kronen auf "Equal Weight" belassen. Nach starkem Start hätten... ► Artikel lesen | |
| ELI LILLY | 919,70 | +0,10 % | Eli Lilly vor dem nächsten Kursschub? Technische Analyse signalisiert begrenztes Abwärtsrisiko und neue Höchststände | Eli Lilly bleibt aus technischer Sicht ein attraktiver Large Cap mit intaktem Aufwärtstrend und begrenztem Abwärtsrisiko. Die jüngste Konsolidierung nach dem steilen Anstieg wird im Kern als normale... ► Artikel lesen | |
| ETON PHARMACEUTICALS | 32,560 | -0,09 % | Eton Pharmaceuticals Expands Rare Disease Portfolio Through Agreement for U.S. Commercialization Rights to IMPAVIDO (miltefosine) | IMPAVIDO is the first and only FDA-approved oral therapy for visceral, cutaneous, and mucosal leishmaniasis caused by specific Leishmania speciesLeishmaniasis is a rare but potentially life-threatening... ► Artikel lesen | |
| GENERATE BIOMEDICINES | 14,540 | +0,07 % | Generate:Biomedicines: Generate Biomedicines, Inc. Reports First Quarter 2026 Financial Results and Provides Business Update | SOLAIRIA-1 AND SOLAIRIA-2 Phase 3 clinical trials for GB-0895 (anti-TSLP) continue to advance
Clinical trial sites activated for GB-4362 (MMAE neutralizer); first... ► Artikel lesen | |
| FUNCTIONAL BRANDS | 0,106 | -0,09 % | Functional Brands Inc.: Functional Brands Enters into Agreement to Acquire Alchemy, a Gold-Backed Blockchain Settlement Platform, in a $142.9 Million Transaction | Lake Oswego, Oregon--(Newsfile Corp. - May 22, 2026) - Functional Brands Inc. (NASDAQ: MEHA) ("Functional Brands" or the "Company") today announced the execution of a definitive agreement for the... ► Artikel lesen | |
| SCHOTT PHARMA | 16,980 | +1,92 % | JEFFERIES stuft Schott Pharma auf 'Hold' | NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat das Kursziel für Schott Pharma von 15,50 auf 17,30 Euro angehoben, aber die Einstufung auf "Hold" belassen. Der neu verantwortliche Analyst... ► Artikel lesen | |
| PFIZER | 22,380 | +0,27 % | Unterbewertet - Analysten rücken LifeScience in den Fokus! Bayer, Vidac Pharma, Novo Nordisk und Pfizer im Check | Dass Analysten den LifeScience-Bereich zuletzt wieder besser einschätzen, zeigt die dynamische Kursziel-Anpassung der DZ Bank für Bayer. Der starke Jahresstart des Pharma- und Agrarchemiekonzerns führt... ► Artikel lesen | |
| MERCK & CO | 105,14 | -0,32 % | MSD investiert CHF 60 Millionen in neuen Hauptsitz in Luzern / Eröffnung durch Bundesrätin Elisabeth Baume-Schneider | Luzern (ots) - MSD Merck Sharp & Dohme, ein global führendes Biopharmaunternehmen, hat heute seinen neuen Schweizer Hauptsitz "One Roof" im Luzerner Stadtteil Rösslimatt feierlich eröffnet. An der offiziellen... ► Artikel lesen | |
| GSK | 22,130 | -0,05 % | GSK: Japan's MHLW Expands Eligible Population For Arexvy | BRUSSELS/FRANKFURT/PARIS (dpa-AFX) - GSK plc (GSK, GSK.L) announced that Japan's Ministry of Health, Labour and Welfare has expanded the eligible population for RSV vaccine, Arexvy, to include... ► Artikel lesen | |
| AQUESTIVE THERAPEUTICS | 4,120 | 0,00 % | Aquestive Therapeutics, Inc.: Aquestive Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update | Reaffirms guidance to resubmit Anaphylm (dibutepinephrine) sublingual film NDA in Q3 2026Affirms existing clinical data is sufficient for submitting regulatory applications in Canada, European Union... ► Artikel lesen | |
| BRIGHT MINDS BIOSCIENCES | 83,70 | +0,24 % | Bright Minds Biosciences GAAP EPS of -$1.09 for three months ended March 31 | ||
| ZOETIS | 70,14 | +0,11 % | ZOETIS INC - Stabilität als strategische Zone |
SYNACT PHARMA AB gehört der Branche Pharma an. Die relative Kursveränderung beträgt aktuell +1,68 % bei einem Aktienkurs von 1,330 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu SYNACT PHARMA AB finden Sie auf Wallstreet Online.